Safety of topical medications in the management of pediatric atopic dermatitis: an updated systematic review.

Data discussed here support the use of steroid-sparing medications (tacrolimus, pimecrolimus, crisaborole, delgocitinib) as safe options with minimal adverse events for managing pediatric AD, although a larger number of TCI studies reported burning and pruritus compared to TCS studies. TCS was the only medication class associated with reports of skin atrophy in this review. The tolerability of these adverse events should be considered when treating young children. This review was limited to English language publications and the variable safety reporting of trial investigators. Many newer medications were not included due to pooled adult and pediatric safety data that did not meet inclusion criteria.